Related Experiment Video
Updated: Jun 11, 2025
12:40
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
28.7K
Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment
Jens Peter Panse1, Britta Höchsmann2, Jörg Schubert3
1Department of Hematology, Oncology, University RWTH Medical School, Aachen, Germany.
Summary
Terminal complement inhibitors (CI) reduce intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH). Proximal CIs address extravascular hemolysis, improving anemia and quality of life, but more data are needed for first-line treatments.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Paroxysmal nocturnal hemoglobinuria (PNH) involves intravascular hemolysis (IVH) due to complement system dysregulation.
- IVH causes anemia, fatigue, and thrombophilia, significantly impacting patient health.
- Terminal complement cascade inhibitors have improved survival by blocking IVH.
Purpose of the Study:
- To compare the efficacy of terminal and proximal complement inhibitors in treating PNH.
- To evaluate the role of proximal complement inhibitors in managing extravascular hemolysis (EVH).
- To highlight the need for treatment algorithms in first-line PNH therapy.
Main Methods:
- Review of clinical data on terminal complement inhibitors (e.g., eculizumab, ravulizumab).
- Analysis of studies on proximal complement inhibitors (e.g., pegcetacoplan, danicopan, iptacopan).
- Assessment of patient outcomes including hemoglobin levels, absolute reticulocyte counts (ARC), and quality of life (QoL).
Main Results:
- Terminal CIs effectively reduce IVH and improve survival in PNH patients.
- Proximal CIs can normalize hemoglobin and ARC in patients with significant EVH, enhancing QoL.
- Some patients on terminal CIs still experience relevant EVH, necessitating alternative treatments.
Conclusions:
- Proximal CIs offer a valuable therapeutic option for PNH patients with persistent EVH.
- A treatment algorithm is needed to guide the selection of first-line therapy for PNH.
- Further real-world data are required to confirm long-term benefits of proximal CIs, particularly in first-line settings.
More Related Videos
Related Concept Videos
01:27Disorders of Erythrocytes
897
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
897
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
180
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
180
01:24Disorders of Hemostasis
738
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
738
01:30Pulmonary Hypertension: Classification and Pathogenesis
152
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
152
01:24Hemodialysis II: Procedure and Complications
2
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
2
02:45Blood Transfusion and Agglutination
10.7K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.7K